Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-07-01
2008-03-11
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S526000, C549S298000
Reexamination Certificate
active
07342114
ABSTRACT:
4-O esters of podophyllotoxin and 4′-demethylepipodophyllotoxin are provided. The compounds are 4-O esters of an alkanoic acid or substituted alkanoic acid and podophyllotoxin and 4′-demethylepipodophyllotoxin. The compounds are useful for treating cancer.
REFERENCES:
patent: 3524844 (1970-08-01), Keller-Juslen
patent: 4965348 (1990-10-01), Saulnier et al.
patent: 6096336 (2000-08-01), Cao et al.
patent: 2837824 (2002-03-01), None
Nagao, Y et al ‘different mechanisms of action of long chain fatty acid esters of posophyllotoxin and esters of epipodophyllotoxin against P388 lymphocytic leukemia in mice’ CA 117:124013.
Nagao, Y et al ‘Preparation and testing of podophyllotoxin derivatives as neoplasm inhibitiors’ CA 112:7272.
Greenwald, RB et al ‘Drug delivery of anticncer agents: water soluble 4-polyethylene glycol derivatives ofhte lignan, podophyllotoxin’ CA 132:15517.
Lie, Ken Jie et al ‘Synthesis and spectral characteristics of some unusual fatty esters of podophyllotoxin’ CA 132:3273.
Weller et al, 21-day oral Etoposide for metastatic breast cancer: a phase II study and review of the literature, PMID: 10857889 (2000).
Wang, YG et al, Syntheses and structure-activity relationship ofpodophyllotoxin derivatives as potential anticancer drugs, CA 127:149030 (1997).
Pan, J et al, Syntesis of epipodophyllotoxin carboxylates and antitumor activity in vitro, CA 129:175488 (1998).
Fischer, PM et al, Preparation of peptide derivatives for improved delivery of drug therapeutic agents, CA 132:93654 (2000)0.
Mantle, Therapeutic applications of medicinal plants in the treatment of breast cancer: a review of their pharmacology, efficacy and tolerability, PMID: 11059361 (2000).
Pradhan, SN Effect of Various Drugs on the Tumor-necrotizing Activity of Several Chemical Agents in Mice, Cancer Research (1956) 1062-8.
Pan et al. STN Accension No. 1998:291310; Document No. 129:175488; Abstract of Yaoxue Xuebao 1997, 32(12), 898-901.
Brodin et al.,Acta Pharm Suec. 19: 267-284 (1982).
Forssen, et al.,Cancer Res, 52: 3255-3261 (1992).
Fung et al.,Biomater. Artif. Cells. Artif. Organs16: 439 et seq. (1988).
Gensler, et al.,J. Med. Chem. 20:5 635-644 (1977).
Hansen, et al.,Acta Chemi. Scand. 47: 1190-1200 (1993).
Khokhar, et al.,J. Med. Chem, 34: 325-329 (1991).
Lasic,Nature335: 279-280 (1992).
Lee et al.,Bio&Med. Chem. Ltrs. 7:22: 2897-2902 (1997).
Levy et al.,J. Pharm. Sci. 72:10: 1158-1160 (1983).
Perez-Soler, et al.,Cancer Res., 50: 4260-4266 (1990).
Santangelo et al.,Syn. Comm., 26:15: 2863-2873 (1996).
Supersaxo et al.,Pharm Res. 8: 1280-1291 (1991).
Thurston et al.,J. Med. Chem. 32: 604-608 (1989).
Yokoyama et al.,Cancer Res. 51: 3229-3236 (1991).
California Pacific Medical Center
Catholic Healthcare West, DBA St. Mary's Medical Center
Chandrakumar Nizal S.
Foley & Lardner LLP
Seaman D. Margaret
LandOfFree
Podophyllotoxin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Podophyllotoxin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Podophyllotoxin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3962546